Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 09/22 08:43:22 am
643.4 DKK   -0.83%
09/21European ADRs Move Higher in Tuesday Trading
MT
09/20NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
PU
09/20NOVO NORDISK A/S : – Share repurchase programme
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
645.7(c) 643.4(c) 634.4(c) 648.8(c) 643.4 Last
2 177 209 3 511 545 2 238 660 1 712 595 755 904 Volume
+1.46% -0.36% -1.40% +2.27% -0.83% Change
More quotes
Estimated financial data (e)
Sales 2021 137 B 21 644 M 21 644 M
Net income 2021 46 316 M 7 305 M 7 305 M
Net cash position 2021 6 163 M 972 M 972 M
P/E ratio 2021 32,3x
Yield 2021 1,53%
Sales 2022 151 B 23 763 M 23 763 M
Net income 2022 50 734 M 8 001 M 8 001 M
Net cash position 2022 11 195 M 1 765 M 1 765 M
P/E ratio 2022 29,0x
Yield 2022 1,69%
Capitalization 1 486 B 234 B 234 B
EV / Sales 2021 10,8x
EV / Sales 2022 9,79x
Nbr of Employees 45 971
Free-Float 69,8%
More Financials
Company
Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84.3%); - hemophilia treatment products (8.4%): mainly injections of protein; - growth hormones (6%): used for treatment of growth deficiencies in children; - hormone replacement products (1.3%): used for treatment of... 
Sector
Pharmaceuticals
Calendar
11/03 | 01:30amEarnings Release
More about the company
Ratings of Novo Nordisk A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about NOVO NORDISK A/S
09/21European ADRs Move Higher in Tuesday Trading
MT
09/20NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
PU
09/20NOVO NORDISK A/S : – Share repurchase programme
AQ
09/16VC DAILY : Venture Capitalists Push Back Against -2-
DJ
09/14ANALYST RECOMMENDATIONS : Apple, Bank of America, Cisco, DT Midstream, Halliburton...
09/14NOVO NORDISK : Jefferies reiterates its Sell rating
MD
09/13NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
PU
09/07NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
PU
09/06NOVO NORDISK A/S : – Share repurchase programme
AQ
09/02NOVO NORDISK : Berenberg reaffirms its Neutral rating
MD
09/02ANALYST RECOMMENDATIONS : AstraZeneca, Designer Brands, Homeserve, Rio Tinto, Trane Techno..
09/01NOVO NORDISK : Buy rating from Deutsche Bank
MD
08/31NOVO NORDISK A/S : MIT - Drug delivery capsule could replace injections for protein drugs
AQ
08/31MASSACHUSETTS INSTITUTE OF TECHNOLOG : Drug delivery capsule could replace injections for ..
AQ
08/30NOVO NORDISK A/S : Share repurchase programme (Form 6-K)
PU
More news
News in other languages on NOVO NORDISK A/S
09/21Les ADR européens en hausse mardi
09/14OPINIONES DE ANALISTAS DEL DÍA : Inditex, Técnicas Reunidas, STMicroelectronics, Delivery ..
09/14MADRID STOCK EXCHANGE : Tres, dos, inflación
09/14STOCK MARKET PARIS : Trois, deux, inflation
09/14AVIS D'ANALYSTES DU JOUR : STMicroelectronics, Delivery Hero, Sanlorenzo, Tecan, Carlsberg..
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Stock Trading Strategies
NOVO NORDISK A/S - 09/16
No turn-around in sight
BUY
More Stock Trading Analysis
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 648,80 DKK
Average target price 608,04 DKK
Spread / Average Target -6,28%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Executive VP & Head-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S52.07%234 070
JOHNSON & JOHNSON4.54%433 122
ROCHE HOLDING AG9.82%321 584
PFIZER, INC.20.08%246 246
ELI LILLY AND COMPANY36.32%208 668
ABBVIE INC.0.00%189 353